Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35108374

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Mar 3
First author
Huber H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Mar 3;139(9):1264-1265. doi: 10.1182/blood.2021014826.
    note
    Source null
    related pmid
    35238892
    relationship
    Comment in

Authors and identifiers

  1. name
    Huber H
    type
    Author
  2. name
    Edenhofer S
    type
    Author
  3. name
    von Tresckow J
    type
    Author
  4. name
    Robrecht S
    type
    Author
  5. name
    Zhang C
    type
    Author
  6. name
    Tausch E
    type
    Author
  7. name
    Schneider C
    type
    Author
  8. name
    Bloehdorn J
    type
    Author
  9. name
    Fürstenau M
    type
    Author
  10. name
    Dreger P
    type
    Author
  11. name
    Ritgen M
    type
    Author
  12. name
    Illmer T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Huber H
    type
    Author
  2. name
    Edenhofer S
    type
    Author
  3. name
    von Tresckow J
    type
    Author
  4. name
    Robrecht S
    type
    Author
  5. name
    Zhang C
    type
    Author
  6. name
    Tausch E
    type
    Author
  7. name
    Schneider C
    type
    Author
  8. name
    Bloehdorn J
    type
    Author
  9. name
    Fürstenau M
    type
    Author
  10. name
    Dreger P
    type
    Author
  11. name
    Ritgen M
    type
    Author
  12. name
    Illmer T
    type
    Author
bibliography ids
  1. nci-bib-2e7d852e6897eae3c6c73f2d
book metadata
content sha256
0ef867fcc3e5dd9cc3188c55d037550e24276efefd2e1ff06a9f3a8392cc3948
document type
citation
dois
  1. 10.1182/blood.2021013208
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35108374
immutable id
pubmed:35108374@0ef867fcc3e5dd9cc3188c55d037550e24276efefd2e1ff06a9f3a8392cc3948
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
9
name
Blood
nlm unique id
7603509
pages
1318-1329
volume
139
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Mar 3;139(9):1264-1265. doi: 10.1182/blood.2021014826.
    note
    Source null
    related pmid
    35238892
    relationship
    Comment in
outcomes validated
false
pmid
35108374
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
c93f348a87dce50b6020c63be19cba07a9318d5d757caf070b1b244222da0ef6
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Mar 3
precision
day
year
2022
publication types
  1. Clinical Trial
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35108374/
title
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.

Preserved source evidence · Not medical advice